The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.
"We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer," says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.
The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.
Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.
They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.
They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.
On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provide
'"/>
Contact: Michelle Gailiun
michelle.gailiun@osumc.edu
614-293-3737
Ohio State University Medical Center
3-Apr-2006